NEW YORK (Genomeweb News) – Shares of Millipore were up 4 percent at $69.02 in afternoon trade on the New York Stock Exchange after an upgrade to its rating by investment bank Leerink Swann.

The bank raised its rating on Millipore to "outperform" from "market perform." Analyst Isaac Ro said that the change was due to "improving fundamentals and execution."

Millipore "should benefit from exposure to a number of themes that include cell-based H1N1 vaccine production, an improving biologics pipeline, recent product launches, and stimulus funding," wrote Ro.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.